Congresses

Title Yearsort descending
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
The D2AMR group: Discovery and development of Antimicrobials and Mechanisms of drug Resistance 2017
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases  2017
Discovery of new therapies for Buruli ulcer treatment 2017
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON-TUBERCULOUS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS 2018
Anthelmintic avermectins for the treatment of non-tuberculous mycobacteria infections in cystic fibrosis 2018
Caracterización biológica de una nueva serie de compuestos químicos con actividad antimicrobiana 2018
Sesión II: Antimicrobianos (Moderador) 2018
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos 2018
Towards the elucidation of rifampicin/betalactam synergistic interactions against M. tuberculosis 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
Development of a high-throughput method for synergistic drug combinations screening 2018
Repurposing beta-lactams for buruli ulcer treatment 2018
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
Beta-lactams for Tuberculosis Treatment 2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens 2019
TOWARDS THE ELUCIDATION OF THE MODE OF ACTION OF A NEW CHEMICAL SERIES WITH ANTIMICROBIAL ACTIVITY 2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019

Pages